Entresto Tablet, Film Coated
Product Images NDC 71610-806

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Entresto (NDC 71610-806). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71610-806-32 (71610 806 32)

ENTRESTO 49 mg/51 mg film-coated tablets label showing product name, active ingredients Sacubitril and Valsartan, and strength. The label indicates packaging of 780 tablets by Aphena Pharma Solutions - Tennessee, LLC. Storage instructions note temperature control and light resistance. Includes lot number, GTIN, NDC 71610-806-32, batch number, and RX only designation.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Valsartan Structural Formula (Entresto 01)

Chemical structure diagram of sacubitril and valsartan, showing the detailed molecular arrangement of the combined active ingredients in ENTRESTO 49 mg/51 mg film-coated tablets by Aphena Pharma Solutions - Tennessee, LLC.*

FDA Label Image

Figure 1: Effect Of Entresto On Pharmacokinetics Of Coadministered Drugs (Entresto 02)

A forest plot chart showing geometric mean ratios and 90% confidence intervals for area under the curve (AUC) and maximum concentration (Cmax) of various coadministered drugs including Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HCTZ, Metformin, Atorvastatin, and Sildenafil, with change relative to reference on the x-axis.*

FDA Label Image

Figure 2: Pharmacokinetics Of Entresto In Specific Populations (Entresto 03)

A pharmacokinetic chart illustrating geometric mean ratios and 90% confidence intervals comparing AUC and Cmax values for LBQ657 and Valsartan across various population subgroups, including renal and hepatic impairment, age, sex, and race. The x-axis shows change relative to reference for these measures.*

FDA Label Image

Figure 3: Kaplan-meier Curves For The Primary Composite Endpoint (a), Cardiovascular Death (b), And Heart Failure Hospitalization (c) (Entresto 04)

Three Kaplan-Meier line graphs comparing ENTRESTO and Enalapril over time in days. Figure A shows time to first occurrence of cardiovascular death or heart failure hospitalizations. Figure B shows time to occurrence of cardiovascular death. Figure C shows time to first occurrence of heart failure hospitalizations. Each graph features cumulative failure rate percentages over approximately 1260 days, with hazard ratios and confidence intervals indicated.*

FDA Label Image

Figure 4: Primary Composite Endpoint (cv Death Or Hf Hospitalization) (Subgroup Analysis)

A forest plot chart comparing hazard ratios with 95% confidence intervals for various subgroups of patients treated with ENTRESTO (Sacubitril and Valsartan) versus Enalapril. The chart lists subgroups such as age, gender, weight, race, region, NYHA class, kidney function, diabetes status, blood pressure, ejection fraction, atrial fibrillation, and other clinical factors. The hazard ratios indicate relative treatment effects with a scale from ENTRESTO better to Enalapril better.*

FDA Label Image

Figure 5: Mean Number Of Events Over Time For The Primary Composite Endpoint Of Total Hf Hospitalizations And Cv Death (Entresto 09)

A line graph titled 'Total Heart Failure Hospitalizations and CV Death in PARAGON-HF' showing mean number of events per 100 patients over time in days since randomization up to 1440 days. It compares outcomes for patients treated with ENTRESTO versus Valsartan, with ENTRESTO showing a consistently lower mean number of events. Risk population numbers for both groups are displayed below the x-axis at various time points.*

FDA Label Image

Figure 6: Primary Composite Endpoint Of Total Hf Hospitalizations And Cv Death – Subgroup Analysis (paragon-hf) (Entresto 10)

A forest plot chart comparing ENTRESTO and Valsartan across various subgroups including age, gender, race, region, diabetes status, LVEF, AF history, NT-proBNP levels, SBP, MRA use, ACEi intolerance, eGFR, and NYHA class. The chart shows rate ratios with 95% confidence intervals indicating group-specific effectiveness between ENTRESTO and Valsartan.*

FDA Label Image

Figure 7: Treatment Effect For The Composite Endpoint Of Time To First Hf Hospitalization Or Cv Death By Lvef In Paradigm-hf And Paragon-hf (Entresto 11)

A dual-panel line chart comparing hazard ratios of ENTRESTO versus enalapril (left panel) and ENTRESTO versus valsartan (right panel) across left ventricular ejection fraction percentages at screening. Each panel shows a solid line for hazard ratio and dashed lines indicating the 95% confidence interval, with the x-axis representing ejection fraction percentages and the y-axis representing hazard ratios.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.